Diabetes ComplicationsPharmacological Treatments

Tirzepatide vs GLP-1 RA in Type 2 Diabetes


JAMA Network Open


Tirzepatide vs GLP-1 RA in Type 2 Diabetes

Summary

This study analyzed the association of tirzepatide with all-cause mortality and adverse cardiovascular and kidney outcomes compared with GLP-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes. Results indicated significantly lower hazards of all-cause mortality, major adverse cardiovascular events (MACEs), kidney events, acute kidney injury, and major adverse kidney events for patients treated with tirzepatide compared to GLP-1 RA treatment. The retrospective cohort study utilized data from the US Collaborative Network of TriNetX, involving 140,308 patients. Findings suggest tirzepatide provides superior clinical benefits for cardiovascular and kidney health in type 2 diabetes management compared with GLP-1 RAs, supporting its integration into therapeutic strategies for this patient population.

Study Design

Interventions

Tirzepatide therapyGLP-1 receptor agonist therapy

Study Type

Cohort

Outcomes

All-cause mortalityMajor adverse cardiovascular eventsKidney eventsAcute kidney injury

Duration and Size

medium–term_3–12_mo
Mega size (5000+)

Study Population

Age Range

Middle Aged (40-64)Young Adult (19–39)

Sex

MaleFemale

Geography

North America

Other Criteria

with T2 Diabetes

Methodology

A retrospective cohort study leveraging TriNetX database with propensity score matching and Cox proportional hazards regression for outcome analysis.

Interventions

Interventions included tirzepatide administration and comparison with GLP-1 receptor agonists, assessing mortality, cardiovascular, and kidney outcomes.

Key Findings

Tirzepatide treatment was associated with significantly lower risks of mortality and major cardiovascular and kidney events compared with GLP-1 RAs.

Comparison with other Studies

Compared with previous studies, tirzepatide shows superior outcomes in glycemic control, weight loss, and cardiovascular protection, aligning with SURPASS trials but providing novel direct comparison with GLP-1 RAs.

Journal Reference

Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC. Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes. JAMA Netw Open. 2024;7(8):e2427258. doi:10.1001/jamanetworkopen.2024.27258

Related and Discussions

experts

Tirzepatide's Impact on Weight Loss and Glycemic Control

Dr. Louis J. Aronne
experts

Comparative Efficacy of Tirzepatide and Semaglutide

Dr. Andreea Ciudin
experts

Tirzepatide's Role in Cardiovascular Risk Reduction

Dr. Naveed Sattar
experts

Patient Experiences with Tirzepatide in Weight Management

Dr. Deborah B. Horn
experts

Tirzepatide's Mechanism and Clinical Applications

Dr. Louis J. Aronne
online

Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Type 2 Diabetes

PubMed
online

Agonistas del GLP-1: fármacos para la diabetes y pérdida de peso

Mayo Clinic
online

Medicamentos orales e inyectables para la diabetes tipo 2

American Diabetes Association
online

Tirzepatide for the treatment of adults with type 2 diabetes

PubMed Central
online

La diabetes tipo 2: síntomas, causas y tratamientos

WebMD
reddit

A drug approved to treat Type 2 diabetes is extremely effective at reducing obesity, according to a new study.

u/USA_Today
reddit

Comparing the Big 3: Semaglutide, Tirzepatide, and Retatrutide

u/HealthEnthusiast
reddit

How do the new generation of weight loss drugs (Semaglutide, Tirzepatide) work?

u/AskScience
reddit

Dual Agonist of GLP-1 and GIP – Tirzepatide

u/PeptideResearcher
reddit

How Tirzepatide Can Be Effective for Weight Management

u/ZealthyLiving
studies

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

Diabetologia
studies

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
studies

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control and weight loss in type 2 diabetes: a systematic review and network meta-analysis

The BMJ
studies

Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Patients With Type 2 Diabetes: A Retrospective Cohort Study

JAMA Network Open
studies

Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis

Frontiers in Pharmacology
𝕏

In this cohort study of patients with type 2 diabetes mellitus, treatment with tirzepatide was associated with lower hazards of all-cause mortality and major adverse cardiovascular events.

JAMA Network Open
𝕏

Nuevo estudio compara semaglutida y tirzepatida en 18.386 adultos con sobrepeso/obesidad: Primer estudio de efectividad comparada en el mundo real.

Juan Turnes
𝕏

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists.

HCPLive
𝕏

Tirzepatide para el control del sobrepeso y la obesidad marca una nueva era en el tratamiento, permitiendo a muchos lograr una pérdida de peso ≥ 20%.

Marcos Gamboa
𝕏

An observational study found adults with type 2 diabetes have lower risks for death and major adverse cardiovascular and kidney events if they use tirzepatide compared with GLP-1 receptor agonists.

Endocrine Today
youtube

Once-Weekly Tirzepatide for Obesity

NEJM
youtube

Mounjaro® (tirzepatide) Mechanism of Action for Type 2 Diabetes

Eli Lilly and Company
youtube

ADA 2021 – The SURPASS trials so far: Tirzepatide

Diabetes Knowledge in Practice
youtube

Tirzepatide: A New Frontier for Diabetes Management

Drug Information Soundcast in Clinical Psychiatry
youtube

SURPASS-5: Tirzepatide in people with insulin-dependent type 2 diabetes

Diabetes Knowledge in Practice

Stay informed. Stay ahead.

Subscribe now for the latest breakthroughs, expert insights, and cutting-edge updates in diabetes care—delivered straight to your inbox.